Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04594798
Title A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Rochester
Indications

diffuse large B-cell lymphoma

follicular lymphoma

B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab

Age Groups: senior
Covered Countries USA


No variant requirements are available.